Eris Lifesciences Limited announced the outcome of its Board meeting held on February 13, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The results were submitted with an unmodified limited review report. Key financial disclosures included a nine-month consolidated revenue of ₹2,378.38 Crore and a net profit after tax of ₹368.40 Crore.
Outcome of Board Meeting on February 13, 2026
The Board of Directors of Eris Lifesciences Limited convened on Friday, February 13, 2026, and subsequently approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The meeting commenced at 11:30 A.M. and concluded at 01:10 P.M. The necessary limited review reports accompanying the financial results were also placed on record, confirming an unmodified opinion.
Consolidated Financial Highlights (Nine Months Ended Dec 31, 2025)
The filing provided detailed consolidated financial performance metrics. For the nine months ended December 31, 2025, the Group reported:
- Total Revenue from operations: ₹2,372.86 Crore (compared to ₹2,188.34 Crore in the previous corresponding period).
- Total Income: ₹2,378.38 Crore.
- Profit after tax (Net profit for the period): ₹368.40 Crore (compared to ₹273.02 Crore in the previous corresponding period).
- Earnings Per Share (Diluted): 24.77 (compared to 18.96 in the previous corresponding period).
Standalone Financial Highlights (Nine Months Ended Dec 31, 2025)
The standalone financial performance was also reported:
- Total Income: ₹1,615.77 Crore.
- Net profit for the period: ₹252.65 Crore.
- Earnings Per Share (Diluted): 18.52.
Significant Corporate Developments Noted
Several operational and strategic changes impacted the results:
- New Labour Codes Impact: Effective November 21, 2025, the assessment of the new Labour Codes resulted in an increase in gratuity and leave liability, leading to an Exceptional Item charge of ₹17.24 Crores for the quarter and nine months ended December 31, 2025.
- Acquisition of Swiss Parenterals Limited: Subsequent to the quarter, on January 16, 2026, the Company completed a preferential allotment of equity shares to the non-controlling interest holder of Swiss Parenterals Limited. This transaction resulted in Swiss becoming a wholly owned subsidiary effective from that date.
- Scheme of Arrangement: The Boards approved a Composite Scheme of Arrangement involving ETL, AHL, and EOHPL, subject to necessary regulatory approvals.
- ESOP Allotment: During the nine months ended December 31, 2025, 54,322 ordinary shares were allotted under the Employee Stock Option Scheme 2021, increasing the issued and paid-up Share Capital to ₹13.62 crore.
Key Ratios (Standalone Performance)
Key standalone financial health indicators for the nine months ended December 31, 2025, show improved margins compared to the prior year:
- Operating Margin Percent: 35.37% (up from 19.02% for the same period last year).
- Net Profit Margin Percent: 16.36% (up from 3.63% for the same period last year).
Source: BSE
